Amylin greenshoe exercised, raising follow-on stock sale to $534.75 million

By Lisa Kerner

Erie, Pa., April 4 - Amylin Pharmaceuticals, Inc. said the underwriters of its follow-on stock offering exercised the 1.5 million share over-allotment option in full, raising the size of the deal to 11.5 million shares or $534.75 million.

Amylin originally priced 10 million shares on March 30 at $46.50 for proceeds of $465 million.

Morgan Stanley & Co. Inc. was the bookrunner and co-lead manager, with Goldman, Sachs & Co. acting as a co-lead manager of the offering. Co-managers for the offering are Bear, Stearns & Co. Inc. and Lehman Brothers Inc.

Amylin Pharmaceuticals is a San Diego-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.